文献速递妇产影像US

胎盘植入谱系疾病的产前超声分期系统

Prenatal ultrasound staging system for placenta accreta spectrum disorders.
PubMed 文献 · Ultrasound Obstet Gynecol · 2019-05-06

该研究对259例前置胎盘妇女进行回顾性分析,基于超声征象建立胎盘植入谱系疾病(PAS)分期系统(PAS0-PAS3),发现分期越高,估计失血量、输血量、手术时间、住院时间及手术并发症风险均显著增加,且与FIGO临床分级系统相关。

要点

  • PAS超声分期基于前置胎盘妇女的超声征象:PAS0无植入征象或仅有胎盘陷窝但无子宫膀胱界面异常;PAS1至少具备胎盘陷窝、透明带消失或膀胱壁中断中的两项;PAS2为PAS1加子宫膀胱连接处血供增多;PAS3为PAS1或PAS2加子宫下段前壁下份血供增多可能延伸至宫旁区域。
  • PAS分期每增加一级,估计失血量增加314 mL(95%CI 230-399),输注浓缩红细胞增加1.74单位(95%CI 1.33-2.15),手术时间增加38.8分钟(95%CI 31.6-46.1),住院时间增加0.83天(95%CI 0.46-1.27),均P<0.001。
  • PAS严重程度增加与手术并发症独立相关(OR 3.14,95%CI 1.36-7.25,P=0.007),仅PAS3与ICU入住相关(P<0.001)。

核心结论

  • 产前超声分期系统对PAS疾病可行,且与手术结局、胎盘侵入深度及FIGO临床分级系统相关。

研究设计与样本

  • 前瞻性收集数据的二次回顾性分析,纳入259例前置胎盘妇女,基于超声征象分为PAS0至PAS3期,评估与手术结局、胎盘侵入深度及FIGO分级系统的相关性;产前和手术管理未基于该分期系统。

关键影像表现/征象

  • PAS0定义为前置胎盘无侵入超声征象或仅有胎盘陷窝但无子宫膀胱界面异常证据。
  • PAS1定义为至少具备胎盘陷窝、透明带消失或膀胱壁中断中的两项。
  • PAS2定义为PAS1加子宫膀胱连接处血供增多。
  • PAS3定义为PAS1或PAS2加子宫下段前壁下份血供增多可能延伸至宫旁区域。

诊断标准与关键数值

  • PAS0平均估计失血量516±151 mL,PAS1为609±146 mL,PAS2为950±190 mL,PAS3为1323±533 mL,随分期增加显著增加。
  • PAS0平均输注浓缩红细胞0.05±0.21单位,PAS1为0.10±0.45单位,PAS2为1.19±1.11单位,PAS3为4.48±2.06单位,随分期增加显著增加。
  • PAS1平均输注新鲜冰冻血浆0.0±0.0单位,PAS2为0.25±1.0单位,PAS3为3.63±2.67单位,从PAS1至PAS3逐渐增加。
  • PAS3平均输注血小板2.37±2.40单位,显著多于PAS0(0.03±0.18)、PAS1(0.0±0.0)或PAS2(0.0±0.0)。
  • PAS3平均手术时间184±32分钟,长于PAS1(153±38分钟)或PAS2(161±28分钟);PAS3平均住院时间7.4±2.1天,长于PAS0(3.4±0.6天)、PAS1(6.4±1.3天)或PAS2(5.9±0.8天)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop a prenatal ultrasound staging system for placenta accreta spectrum (PAS) disorders in women with placenta previa and to evaluate its association with surgical outcome, placental invasion and the clinical staging system for PAS disorders proposed by the International Federation of Gynecology and Obstetrics (FIGO).

METHODS: This was a secondary retrospective analysis of prospectively collected data from women with placenta previa. We classified women according to the following staging system for PAS disorders, based upon the presence of ultrasound signs of PAS in women with placenta previa: PAS0, placenta previa with no ultrasound signs of invasion or with placental lacunae but no evidence of abnormal uterus-bladder interface; PAS1, presence of at least two of placental lacunae, loss of the clear zone or bladder wall interruption; PAS2, PAS1 plus uterovescical hypervascularity; PAS3, PAS1 or PAS2 plus evidence of increased vascularity in the inferior part of the lower uterine segment potentially extending into the parametrial region. We explored whether this ultrasound staging system correlates with surgical outcome (estimated blood loss (EBL, mL), units of packed red blood cells (PRBC), fresh frozen plasma (FFP) and platelets (PLT) transfused, operation time (min), surgical complications defined as the occurrence of any damage to the bladder, ureters or bowel, length of hospital stay (days) and admission to intensive care unit (ICU)) and depth of placental invasion. The correlation between the present ultrasound staging system and the clinical grading system proposed by FIGO was assessed. Prenatal and surgical management were not based on the proposed prenatal ultrasound staging system. Linear and multiple regression models were used.

RESULTS: Two-hundred and fifty-nine women were included in the analysis. Mean EBL was 516 ± 151 mL in women with PAS0, 609 ± 146 mL in those with PAS1, 950 ± 190 mL in those with PAS2 and 1323 ± 533 mL in those with PAS3, and increased significantly with increasing severity of PAS ultrasound stage. Mean units of PRBC transfused were 0.05 ± 0.21 in PAS0, 0.10 ± 0.45 in PAS1, 1.19 ± 1.11 in PAS2 and 4.48 ± 2.06 in PAS3, and increased significantly with PAS stage. Similarly, there was a progressive increase in the mean units of FFP transfused from PAS1 to PAS3 (0.0 ± 0.0 in PAS1, 0.25 ± 1.0 in PAS2 and 3.63 ± 2.67 in PAS3). Women presenting with PAS3 on ultrasound had significantly more units of PLT transfused (2.37 ± 2.40) compared with those with PAS0 (0.03 ± 0.18), PAS1 (0.0 ± 0.0) or PAS2 (0.0 ± 0.0). Mean operation time was longer in women with PAS3 (184 ± 32 min) compared with those with PAS1 (153 ± 38 min) or PAS2 (161 ± 28 min). Similarly, women with PAS3 had longer hospital stay (7.4 ± 2.1 days) compared with those with PAS0 (3.4 ± 0.6 days), PAS1 (6.4 ± 1.3 days) or PAS2 (5.9 ± 0.8 days). On linear regression analysis, after adjusting for all potential confounders, higher PAS stage was associated independently with a significant increase in EBL (314 (95% CI, 230-399) mL per one-stage increase; P < 0.001), units of PRBC transfused (1.74 (95% CI, 1.33-2.15) per one-stage increase; P < 0.001), units of FFP transfused (1.19 (95% CI, 0.61-1.77) per one-stage increase; P < 0.001), units of PLT transfused (1.03 (95% CI, 0.59-1.47) per one-stage increase; P < 0.001), operation time (38.8 (95% CI, 31.6-46.1) min per one-stage increase; P < 0.001) and length of hospital stay (0.83 (95% CI, 0.46-1.27) days per one-stage increase; P < 0.001). On logistic regression analysis, increased severity of PAS was associated independently with surgical complications (odds ratio, 3.14 (95% CI, 1.36-7.25); P = 0.007), while only PAS3 was associated with admission to the ICU (P < 0.001). All women with PAS0 on ultrasound were classified as having Grade-1 PAS disorder according to the FIGO grading system. Conversely, of the women presenting with PAS1 on ultrasound, 64.1% (95% CI, 48.4-77.3%) were classified as having Grade-3, while 35.9% (95% CI, 22.7-51.6%) were classified as having Grade-4 PAS disorder, according to the FIGO grading system. All women with PAS2 were categorized as having Grade-5 and all those with PAS3 as having Grade-6 PAS disorder according to the FIGO system.

CONCLUSION: Ultrasound staging of PAS disorders is feasible and correlates with surgical outcome, depth of invasion and the FIGO clinical grading system. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Cali G, Forlani F, Lees C, et al. Prenatal ultrasound staging system for placenta accreta spectrum disorders. Ultrasound Obstet Gynecol. 2019. PMID: 30834661. doi:10.1002/uog.20246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。